


Chronic graft versus host disease detected by tissue-specific cell-free DNA methylation biomarkers

Batia Avni, ... , Ruth Shemer, Yuval Dor

J Clin Invest. 2023. <https://doi.org/10.1172/JCI163541>.

Clinical Research and Public Health In-Press Preview

Graphical abstract



Find the latest version:

<https://jci.me/163541/pdf>



Chronic graft versus host disease detected by tissue-specific cell-free DNA methylation biomarkers

Batia Avni^{1,*}, Daniel Neiman^{2,*}, Elior Shaked², Ofer Gal-Rosenberg², Sigal Grisariu¹, Mona Kuzli¹, Ilai Avni⁶, Andrea Fracchia¹, Polina Stepensky¹, Tsila Zuckerman⁴, Ahinoam Lev-Sagie⁵, Ilana Fox-Fisher², Sheina Piyanzin², Joshua Moss², Seth Salpeter², Benjamin Glaser³, Ruth Shemer^{2,&}, Yuval Dor^{2,&}

¹Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

²Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, the Hebrew University-Hadassah Medical School, Jerusalem, Israel

³Endocrinology and Metabolism Service, Hadassah University Medical Center and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

⁴Hematology Institute and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.

⁵Department of Obstetrics and Gynecology, Hadassah University Medical Center and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

⁶Faculty of Data and Decision Sciences, Institute of Technology - Technion, Haifa, Israel

* Co-first authors

& Corresponding authors:

Batia Avni, Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center. Phone 972-50-8573971, email batiaavni@gmail.com.

Ruth Shemer, Department of Developmental Biology and Cancer Research, the Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. Phone 972-54-2468645, Fax 972-2-6757482 Email shemer.ru@mail.huji.ac.il

Yuval Dor, Department of Developmental Biology and Cancer Research, the Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. Phone 972-54-2468645, Fax 972-2-6757482 Email yuval.dor1@mail.huji.ac.il

Conflict of interest statement: BA, BG, RS and YD have filed patents on DNA methylation and liquid biopsies. All other authors declare no conflict of interest.

Abstract

Background: Accurate detection of graft versus host disease (GVHD) is a major challenge in the management of patients that undergo hematopoietic stem cell transplantation (HCT). Here we demonstrated the use of circulating cell-free DNA (cfDNA) for detection of tissue turnover and chronic GVHD (cGVHD) in specific organs.

Methods: We established a cocktail of tissue-specific DNA methylation markers and used it to determine the concentration of cfDNA molecules derived from the liver, skin, lungs, colon and specific immune cells in 101 HCT patients.

Results: Patients with an active cGVHD showed elevated concentration of cfDNA, as well as tissue-specific methylation markers that agreed with clinical scores. Strikingly, transplanted patients with no clinical symptoms had abnormally high levels of tissue-specific markers, suggesting hidden tissue turnover even in the absence of evident clinical pathology. An integrative model taking into account total cfDNA concentration, monocyte/macrophage cfDNA levels and Alanine transaminase (ALT) was able to correctly identify GVHD with a specificity of 86% and precision of 89% (AUC of 0.8).

Conclusions: cfDNA markers can be used for the detection of cGVHD, opening a window into underlying tissue dynamics in patients that receive allogeneic stem cell transplants.

Funding: This work was supported by grants from the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, The Israel Science Foundation, the Waldholtz / Pakula family, the Robert M. and Marilyn Sternberg Family Charitable Foundation and the Helmsley Charitable Trust (to Y.D).

Introduction

Hematopoietic stem cell transplantation (HCT) is an essential and often the sole curative treatment strategy for high risk hematologic malignancies (1). Graft versus host disease (GVHD), the foremost complication of allogeneic HCT, is a major limitation of this procedure, accounting for deleterious effects on quality of life and increased mortality from HCT (2, 3). Current diagnosis of acute (aGVHD) and chronic GVHD (cGVHD) in bone marrow transplant patients is based on inaccurate, operator-dependent clinical markers, and less often on biopsies. These methods are time consuming, costly, invasive and yield late-stage diagnoses that negatively affect morbidity and mortality. In addition, current practice lacks accurate biomarkers for prediction of disease occurrence, identification of disease onset, prediction of disease response to treatment and accurate assessment of the actual response to treatment (4). Multiple prognostic and diagnostic biomarkers for cGVHD have been proposed, including IL2R α , aminopeptidase N (CD13), IL4, IL6, TNF α , ST2, OPN, chemokine ligands such as CXCL9, CXCL10, and CXCL11 (5-14), cellular biomarkers including immune cells subpopulations (15-18), miRNA (19) and others. However, none of these biomarkers have been clinically validated. In addition, all these markers are indicative of immune system derangement, lacking information on the damaged tissue targeted by the allo-immune process. Thus, there is an unmet need for simple objective tools that can aid the treating physician in easier identification, scoring and assist personalization of management in patients suffering from cGVHD.

Classic liquid biopsies analyze circulating cell-free DNA (cfDNA) via genetic variations or mutations in the DNA of a fetus, a tumor or a transplanted solid organ. However, these approaches are blind to DNA released from cells with a normal genome, as would occur in organs damaged

by pathologies such as GVHD. We and others have previously shown that tissue-specific DNA methylation patterns can provide powerful, universal biomarkers for detecting the tissue origins of cfDNA, reflective of elevated turnover or damage in specific organs and regardless of the underlying pathology (20-22). For example, we showed that genomic loci specifically unmethylated in lung epithelial cells or in hepatocytes can serve as cfDNA biomarkers detect specific lung or liver injury (20-26).

The aim of this study was to establish a set of affordable highly specific and sensitive methylation markers for cell types relevant to patients at risk for developing cGVHD, to examine their utility for detection of damage to specific organs in patients with clinically suspected cGVHD, and to create a cfDNA-based model that can assist the treating physician in surveillance and treatment decisions.

Results

DNA methylation markers for targeted assessment of cGVHD-relevant tissue damage

We compared publicly available methylomes of specific human tissues (21) and identified genomic loci containing CpG sites that are uniquely unmethylated in specific tissues or cell types, relevant to cGVHD. These included hepatocytes (5 markers), skin (5 markers), lung epithelial cells (10 markers) and intestinal epithelial cells (8 markers). We designed multiplex PCR cocktails to amplify all these loci from genomic DNA after bisulfite conversion, and sequenced the products to determine the fraction of unmethylated DNA molecules present in the starting material. Figure 1 shows the fraction of methylation blocks from each marker locus that were unmethylated in the indicated samples. As we have shown previously, molecules containing multiple unmethylated

CpG sites could be assigned with extreme specificity to a given tissue of origin. We also spiked genomic DNA from specific tissues into genomic DNA of leukocytes to determine assay sensitivity and linearity and found that as little as 0.5% from the target tissue could be robustly identified when present in a mixture (not shown). These findings establish a cocktail of DNA methylation markers that can be used to identify DNA derived from the liver, skin, lungs and intestine with extreme specificity and sensitivity. We also used methylation markers specific to selected immune and inflammatory cell types: neutrophils, eosinophils, monocytes, B lymphocytes and T lymphocytes (including CD8+ and regulatory T cells); all of which showed extreme specificity and sensitivity (27).

Elevated cfDNA levels in HCT patients with and without clinical GVHD

The overall scheme of the experiment is shown in Figure 2. We recruited a total of 101 HCT patients, obtained blood samples, and recorded clinical cGVHD score as well as blood counts and standard blood biochemistry. We determined plasma cfDNA concentration and methylation patterns, compared findings to clinical and biochemistry data, and then developed and validated a model for inference of cGVHD based on cfDNA parameters combined with blood biochemistry markers. The characteristics of the 101 recruited patients and samples are detailed in Supplementary Tables S2-4 and in the Methods section.

We compared total and tissue-specific cfDNA concentration in samples from healthy individuals (median age 37 years old (range 24-68), 58% females), samples from HCT patients that had no evidence of from HCT patients defined by the treating physician as having clinically evident

cGVHD . The NIH 2014 criteria were used for defining disease severity (mild, moderate and severe) and organ scoring (0-3).

Analyzing 101 samples from 101 patients, HCT patients suffering from cGVHD (in any organ) had statistically significant higher concentrations of total cfDNA compared to HCT patients with no clinical evidence of cGVHD ($p<0.0001$) (Figure 3A). Total cfDNA levels in HCT patients were similar to those in healthy controls ($p=0.63$).

CfDNA signals from skin ($p=0.0188$), intestine ($p=0.009$), liver ($p=0.0023$) and lungs ($p=0.0050$) were also significantly higher in the clinically evident cGVHD group compared to the group of patients who did not meet the NIH 2014 criteria for cGVHD (Figure 3B-E). In addition, the concentration of cfDNA originating from GI, liver and lung was significantly higher in patients who underwent HCT with no evidence of clinical GVHD compared to healthy controls ($p=0.0002$, $p=0.0003$, $p<0.0001$, respectively) (Figure 3C-E). Moreover, cfDNA originating from skin and liver significantly correlated with organ specific clinical GVHD presence (score 0 versus score 1-3) ($p=0.0022$, $p=0.0003$, Supplementary Figures S1A and S1C, respectively). Interestingly, HCT patients with and without lung cGVHD (score 0 vs 1-3) had significantly higher levels of lung cfDNA compared with healthy controls ($p<0.0001$), but lung cfDNA did not correlate with the presence of clinical lung score (Supplementary Figure S1B).

Analysis of immune-derived cfDNA showed a significantly higher concentration of cfDNA originating from neutrophils, monocytes, eosinophils, B and T lymphocytes in HCT patients diagnosed with clinical cGVHD compared with patients who were not (Figure 4). cfDNA from neutrophils, T cells and CD8⁺ T cells was elevated in HCT patients that have no clinical cGVHD compared with healthy volunteers (Figure 4A, E, F).

We next sought to identify correlations between cfDNA parameters and cGVHD clinical scores among HCT patients. We produced a correlation matrix for all 101 plasma samples for which all tested parameters were available. cfDNA parameters were highly correlated internally (for example, samples with high concentration of total cfDNA tended to also have high levels of organ specific cfDNA) (Figure 5 and Supplementary Figure S2), and there was a significant internal correlation among cGVHD clinical scores (between cGVHD severity assessment and specific organ grading) (Supplementary Figures S3 and S4). Moreover, we found a significant correlation between clinical cGVHD severity assessment and total cfDNA as well as organ specific cfDNA levels (Figure 5 and Supplementary Figures S3-5).

A combined score for blood-based detection of cGVHD

We wished to create a model which could aid the treating physician to predict the likelihood that a patient has active cGVHD. Employing Shapley analysis on 17 clinical and cfDNA features (see Methods) yielded positive Shapley values for 7 features (ALT, total cfDNA, cfDNA of monocytes, cfDNA of skin, GGTP, cfDNA of neutrophils and cfDNA of eosinophils). Figure 6A shows distribution graphs for these features, and Figure 6B shows the average absolute SHAP value for each individual feature. We conducted repeated 5-fold cross-validations across these 7 feature sets, starting from the feature having the highest value (ALT) and sequentially adding the next feature in line (ALT and total cfDNA; ALT, total cfDNA, cfDNA of monocytes etc.). The metrics (specificity, NPV, PPV, AUC and precision) for each number of features selected are illustrated in Figure 7. Notably, the three first features maximize the AUC, as well as displaying favorable behavior across the other metrics. Therefore, we opt for these three features (consisting of ALT, total cfDNA and cfDNA of monocytes) as the optimal feature set. Recall, specificity, AUC, NPV

and PPV of logistic regression models trained using only ALT, only cfDNA features (total cfDNA and cfDNA of monocytes) and all three features are shown in Figure 8A. The ROC curves of these models are shown in Figure 8B.

Finally, we compared the performance of our models to the exact equivalent set of models, where, instead of using a constrained optimization, we used an unconstrained optimization (allowing negative coefficients). Shapley values are shown for all 17 features (Supplementary Figure S6). The metrics (specificity, NPV, PPV, AUC and precision) for each n are illustrated in Supplementary Figure S7. Favorable behavior across all metrics was reached at $n = 6$ (ALT, GGTp, total cfDNA, cfMonocytes, cfEosinophils, ALP) and repeated 5-fold cross-validation was performed to compare the recall, specificity, AUC, NPV and PPV of logistic regression models trained using these features (Supplementary Figure S8A), as well as the ROC curves of these models (Supplementary Figure S8B).

Evidently, both constrained and unconstrained optimization techniques demonstrate comparable performance, suggesting minimal overfitting with either optimization technique. Moreover, the findings emphasize the high predictive capability of a small set of features, consisting of biochemical and cfDNA measurements. This aligns with our hypothesis that cGVHD leads to increased cell death, consequently elevating the levels of the observed markers.

Discussion

Our study shows that tissue-specific DNA methylation patterns can serve as plasma biomarkers for detection of tissue turnover in cGVHD. We demonstrated a general elevation in cfDNA concentration in cGVHD patients, and an elevation of cfDNA from specific organs as well as

immune and inflammatory cells. Combining cfDNA markers with standard biochemical markers allowed us to discriminate patients with and without cGVHD with good sensitivity, accuracy and precision, suggesting feasibility of a blood-based objective assessment of disease.

In agreement with our findings, it has been demonstrated that mitochondrial cfDNA (COX1 DNA) is higher in patients undergoing SCT compared to normal controls and correlates with the presence of cGVHD (29). To our knowledge, this is the first report of potential tissue-specific cfDNA utility in the context of chronic GVHD. Our findings are consistent with, and expand upon, recent studies that focused on the distinct setting of acute GVHD (30). Cheng et al used a smaller number of patients (n=27) and performed shallow whole genome bisulfite sequencing followed by deconvolution, to assess the levels of cfDNA from different recipient sources. Their key finding was that acute GVHD (within the first 3 months after HCT) was associated with elevated levels of cfDNA from solid organs (multiple tissues combined). Waterhouse et al demonstrated substantial differences in the concentration of one colon specific and one liver specific cfDNA marker in 10 and 14 patients with liver and colon aGVHD respectively. Moreover, they have demonstrated a decline in these markers in patients successfully treated. The clinical condition that we studied – chronic GVHD – is more challenging, as clinical manifestation is typically less abrupt and therefore tissue damage/turnover (which might be reflected by elevated cfDNA levels) is likely to increase gradually. In addition, our approach differs from Cheng et al in that we use a PCR-sequencing of targeted methylation markers to assess the contribution of specific cell types – a method that gives up breadth (i.e. information obtained is limited to a pre-planned subset of tissue sources) for specificity, depth, simplicity and low cost. In contrast to the Waterhouse study, our methodology probes multiple indicators for each organ, allowing to examine a broader spectrum of damaged end organs. Altogether, these three studies support the notion that organ

damage/turnover and immune deregulation in GVHD are amenable for a cfDNA methylation-based analysis, and that liquid biopsies can be developed into an objective, quantitative, clinically useful tool aiding the treating physician in diagnosing chronic, as well as acute GVHD.

An important observation of our study was that most HCT patients with no clinically detected GVHD had an elevated concentration of the cfDNA derived from donor T cells and recipient intestine, liver and lung. We propose that this is a reflection of inflammation and increased cellular turnover in HCT patients, which are taking place even while clinically evident organ function remains in the normal range. This idea is consistent with the model proposed by Cooke et al, whereby chronic GVHD develops through early inflammation and tissue injury, chronic inflammation and dysregulated immunity, and eventually aberrant tissue repair leading to fibrosis (31). Our study was not designed to test if elevated cfDNA from a given tissue source is predictive of future cGVHD. Additionally, larger cohorts will be needed to assess the prognostic potential of methylation-based biomarkers. Such studies will also be able to test the provocative idea that elevated tissue-specific cfDNA takes place chronically even without an overt clinical manifestation, reflecting a low level of allogeneic damage to host tissues that is offset by organ regeneration.

Our study also provides a distinct angle on the nature of immune processes taking place in cGVHD. Extensive studies have revealed the involvement of reactive donor T cells (mainly Th/Tc17), thymic dysfunction, reduced memory B-cell formation concomitant with enrichment of alloreactive B cells, reduced levels of T follicular helper cells, macrophage tissue sequestration and activation, and more (3, 16, 17). These studies have typically not characterized immune cell

turnover. Our findings suggest that allogeneic HCT causes high turnover of donor T cells (including CD8 and to a lesser extent regulatory T cells), at any point after HCT and more so during cGVHD. We hypothesize that the elevated turnover of donor adaptive and innate immune cells, even years after HCT, results from the continuous interaction with allogeneic host tissues. The mechanisms and implications of this phenomenon remain to be elucidated. At a practical level, it is possible that combining cfDNA biomarkers of solid tissues with cfDNA biomarkers of inflammatory / immune cells may increase the specificity of liquid biopsies, e.g. will allow to differentiate organ damage due to immune attack from damage due to other etiologies (32). Further studies are needed to examine this intriguing possibility.

Implementation of tissue-specific cfDNA biomarkers in clinical GVHD will require additional studies to optimize specificity and sensitivity and to understand how cfDNA dynamics relate to, and predict, clinical phenotype. We note that the nature of DNA methylation offers a tremendous potential for refining cfDNA analysis. For example, methylation atlases (21, 33) allow to develop new methylation markers that are specific to hepatocytes from different zones in the liver, alveolar or bronchial epithelial cells, epithelial cells of different segments of the intestine, as well as subsets of immune cells such as tissue-specific macrophages. With regard to sensitivity, emerging lessons from cfDNA-based early cancer detection suggest that parallel assessment of multiple specific markers in the same plasma sample can boost sensitivity by increasing the chance of identifying cfDNA from the tissue of interest. Such refinements of cfDNA assays may facilitate discrimination between suggested biological subgroups of GVHD (resolved GVHD, active late acute GVHD, active chronic GVHD, inactive chronic GVHD and no GVHD), which is challenging in the current clinical setting. In particular, it will be important to search for cfDNA biomarkers that distinguish

active chronic from inactive chronic disease, given the relevance for treatment decisions (31). We note that while our results reveal a good correlation between cfDNA and clinical overt cGVHD, there are outliers showing high cfDNA with no clinical disease and low counts with clinically graded disease. We propose that this discrepancy partly results from the inability of the current clinical grading system to accurately assess the active versus inactive state of cGVHD. Longitudinal studies assessing this hypothesis are warranted.

Using multivariate logistic regression, we pinpointed a trio of pivotal features (ALT, total cfDNA concentration and monocyte/macrophage cfDNA concentration) yielding compelling results: specificity of 86%, a positive predictive value (PPV) of 89%, and a robust area under the curve (AUC) value of 0.8. Notably, what sets our approach apart is its efficiency in capitalizing on a balanced selection of one biochemical parameter and two distinct cfDNA parameters. This pragmatic strategy not only streamlines the diagnostic process but also markedly enhances the ability to accurately discern cases of cGVHD. Conceptually, we believe that combined measurements of classical markers such as liver enzymes and cell counts with cfDNA biomarkers is expected to synergize. The reason is that cfDNA provides distinct biological information: it reveals cell turnover (which is different from cell counts); it is a definitive marker of cell death (while cytoplasmic proteins may be released to blood upon transient cell injury); and it is cleared rapidly, revealing information about acute tissue damage. Particularly intriguing is the role of cfDNA derived from monocytes/macrophages, suggesting a pivotal role of macrophage turnover in the context of cGVHD. This observation is consistent with current understanding of the contribution of macrophage infiltration and activation within affected organs to the pathobiology of the disease (34).

Our study has several limitations. First, we acknowledge that the assay used in this study, based on massively parallel sequencing, may pose challenges to implementation in a standard clinical setting. However, as we have shown before, the small number of target loci makes it possible for translation into a simpler version, based on quantitative PCR (20). Such a version will have the advantage of delivering results faster (same day), at a low cost and in a point-of-care setting. Second, the process underlying elevated tissue-specific cfDNA is not fully understood; for example, it could reflect an increased rate of cell death in the tissue of origin, enhanced turnover rate, or disruption of local removal of debris from dying cells. Regardless, elevated cfDNA appears to correlate well with clinical cGVHD. Third, our study was designed for diagnostic purposes only and not for predictive, prognostic or response to treatment purposes. These need to be explored in separate well-designed prospective, longitudinal studies including a large cohort of transplanted patients. This research should delve into the changes in cfDNA patterns over various time points, commencing prior to the conditioning protocol, spanning the transplantation phase, and encompassing the periods of acute and chronic GVHD. Fourth, this is a single center study and further validation studies using independent cohorts from additional centers are needed.

In conclusion, we demonstrate the potential utility of tissue-specific methylation markers for objective and clinically useful detection of chronic GVHD. We envision that cfDNA biomarkers can transform GVHD treatment into a highly personalized process, where patients are monitored by liquid biopsy many times post-transplant and during treatment to monitor disease and adjust treatment.

Methods

Methylation analysis

We prepared cfDNA and measured its concentration (in nanograms per milliliter plasma), then treated with bisulfite to expose the status of methylation and performed multiplex PCR as described (35) to amplify marker loci. PCR products were sequenced on a NextSeq machine, and the fraction of molecules carrying a tissue-specific pattern of methylation was determined. We used this information, averaged over the markers for each tissue, to assess the relative contribution of each tissue to cfDNA. In addition, by multiplying the proportion of cfDNA from each tissue by the total concentration of cfDNA in a sample, we calculated the absolute concentration of cfDNA from each tissue to plasma, expressed in genome equivalents per milliliter plasma, as described (27, 35). Primer sequences of all markers, as well as clinical and methylation data for all samples are provided in Supplementary Tables S1 and S2.

Clinical assessment of HCT patients in the chronic setting

To assess the utility of cfDNA for detecting organ damage in chronic GVHD, we prospectively collected 101 plasma samples from 101 individuals that were >100 days post allogeneic stem cell transplantation, arriving for planned routine clinical follow up, at the BMT day care unit at Hadassah medical center. Patients agreeing to participate, regardless of their cGVHD status, signed an informed consent. Upon each visit blood was drawn for regular blood tests (extra 10 ml of blood was drawn for cfDNA analysis) and the patient underwent a full assessment by the treating physician which included cGVHD grading according to the 2014 National Institute of Health

(NIH) criteria. During the course of this 38-month study, 65 patients were diagnosed at any point with clinically evident cGVHD, while 36 were not found to have clinical signs of cGVHD.

Patient Characteristics

The median age of patients was 47 years. Sixty five percent of the patients were males. The majority of patients were transplanted due to acute myeloid leukemia (57%), had a matched sibling (63%), were treated with a myeloablative conditioning regimen (64%) and received stem cells withdrawn from peripheral blood (PBSC, 92%). Most of the patients (55%) received a transplant from a matched gender while 25% were transplanted from a mismatched donor gender, in a female to male direction.

Fifty-seven percent of the 101 samples were collected from patients with a history of acute GVHD. None had signs of overlap (both acute and chronic) GVHD at the time of sampling. One patient developed liver GVHD one month post Donor Lymphocyte Infusion (DLI). The median time from transplantation was 783 days (range 101-7878 days). Half of the samples (49) were taken from patients receiving one or more immunosuppressive agents at the time of collection. Only seven patients had evidence of CMV viremia at the time of collection. One patient had biopsy proven colitis, which did not show CMV inclusion bodies while none of the remaining six had any evidence for CMV disease. Four patients were treated for CMV infection. Eleven patients had a positive EBV-PCR in peripheral blood (with a median of 300 copies/ml), none of which was clinically significant. One patient was positive in the upper respiratory tract for RSV and one for influenza. One patient had staphylococcus epidermis bacteremia. Chimerism levels were routinely monitored. Ninety eight percent of the samples were obtained from patients with a blood driven STR assay indicating 100% donor-derived hematopoietic cells. Two samples exhibited a donor

chimerism ranging from 88% to 92%, precluding analysis of the relationship between degree of chimerism, cfDNA methylation profiles and a potential relapse. None of the samples were taken at the time of relapse.

Statistical analysis

Assessment of cfDNA plasma levels in healthy controls versus allogeneic transplanted patients with and without clinical signs of cGVHD was performed using nonparametric, unpaired, Mann Whitney test. Analyses were performed using GraphPad Prism (version 10.0.1) and results were considered statistically significant for p-values of ≤ 0.05 .

We used machine learning to evaluate the predictive power of both cfDNA and biochemical measurements in relation to clinical evident cGVHD. We compared multivariate logistic regression (MLR), XG boost and random forest (RF) classifiers on our data set. MLR, XGboost, RF had an average accuracy of 0.74, 0.67, 0.65, respectively, by Repeated-K-fold cross-validation (K=5) with a standard deviation of 0.23, 0.22, 0.3, respectively. As the MLR model had both higher accuracy with similarly robust results by cross-validation, we applied MLR for further analyses. Furthermore, MLR emerges as the most fitting estimator based on the following considerations:

- We anticipate that GVHD will consistently increase the levels of measured markers, signifying increased cell death. Hence, a monotonous model which consistently increases in response to changes in its features, should be appropriate.
- The size of our data does not support models with a large number of parameters – MLR bears a single parameter per measurement, reducing the risk of overfitting.
- MLR inference naturally provides a probability score.

We hypothesize that measurements of cfDNA and blood biochemical values possess significant predictive potential for the presence of cGVHD. We leveraged Shapley values to gauge the magnitude of the predictive capability of each feature. This latter technique offers a principled approach to feature selection, promoting enhanced performance with reduced overfitting. Since we expect higher cell-free DNA levels to indicate cGVHD, we constrained the parameter space of the model to be non-negative for all coefficients. and compared the performance to an unconstrained optimization in order to explore the overfitting potential of the model. A total of 93 samples (for which data was available for all parameters) were used for the analysis. We employed Shapley analysis (28) on a collection of 17 features (comprising of GGT, ALP, ALT, AST, TBil, Total cfDNA level [presented in ng/ml], and organ specific cfDNA: cfSkin, cfLung, cfGI, cfLiver, cfNeutrophils, cfMonocytes, cfEosinophils, cfB cells, cfT cells, cfCD8 cells, cfTregs cell). Next, to robustly validate the predictive potential of the features, we utilized Repeated-K-Fold cross-validation (36). We conducted repeated 5-fold cross-validations across the feature sets given a positive coefficient (constrained optimization). Each set, labeled $n = 1, \dots, 17$, consists of the highest-ranking n features, meaning, set $n=1$ is the single top-ranking feature, set $n=2$ consists of the 2 top ranking features, set $n=3$ of the 3 top ranking features and so on. The metrics (Specificity, NPV, PPV, AUC and Precision) for each n were calculated. The selection of the best feature set was determined based on those achieving the highest AUC (Area Under the Curve) and demonstrating favorable performance across other metrics. We calculated recall, specificity, AUC, NPV and PPV of logistic regression models trained using only the best feature set. A comparison between cfDNA features compared to blood biochemical features and to the combination of both (meaning the entire set) was performed. All analyses were performed using Python 3.10.

Using the model, accuracy ($[(TP+TN)/\text{Total testing samples}] \times 100\%$), specificity ($[TP/(TP+FN)] \times 100\%$), sensitivity ($[TN/(TN+FP)] \times 100\%$), positive predictive value (PPV) ($[TN/(TN+FN)] \times 100\%$) and negative predictive value (NPV)/precision ($[TP/(TP+FP)] \times 100\%$) were measured.

Graphical representation of the tradeoff between specificity and sensitivity was done using the receiver operating characteristics curve (ROC). Area under the curve (AUC) was calculated in order to determine the ability of the classifier to distinguish positive and negative results. Spearman rank correlation was used to determine the significance of correlation between each pair of variables and other parameters.

Study Approval

The study was approved by the Hadassah Medical Center IRB committee and is consistent with the declaration of principles of Helsinki. Written informed consent was received prior to participation.

Data Availability

Primer sequences of methylation markers, as well as clinical and methylation data values for all samples are provided in **Supplementary Tables S1 and S2**. Values for all data points in graphs can be found in the **Supplementary Table S5: Supporting Data Values** file.

Acknowledgements

This work was supported by grants from Israel Innovation authority (to Y.D. and B.A), the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, The Israel Science Foundation, the Waldholtz / Pakula family, the Robert M. and Marilyn Sternberg Family Charitable Foundation and the Helmsley Charitable Trust (to Y.D). Y.D holds the Walter and Greta Stiel Chair and Research grant in Heart studies.

We thank Drs Abed Nasereddin and Idit Shiff from the Interdepartmental Unit of the Hebrew University of Medicine for their support with DNA sequencing.

Authorship Contributions

BA, BG, SS, RS, YD: designing research studies; BA, DN, OGR, SG, IFF, SP: conducting experiments; BA, ES, OGR, IA, BG, SS, RS, YD, JM: analyzing data; BA, SG, MK, AF, PS, TZ, ALS: providing reagents; BA, ES, IA, BG, RS, YD, JM: writing the manuscript.

BA and DN are co-first authors. The order of names in the paper, as well as the order of co-first authors, was determined based on the relative contributions, which were in different areas (study design, patient access and data interpretation; methylation analysis; and statistical analysis).

Conflicts of Interest Disclosures

BA, BG, RS and YD have filed patents on DNA methylation and liquid biopsies. All other authors declare no conflict of interest.

References

1. Gyurkocza B, Rezvani A, and Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. *Expert Rev Hematol*. 2010;3(3):285-99.

2. Nassereddine S, Rafei H, Elbahesh E, and Tabbara I. Acute Graft. *Anticancer Res.* 2017;37(4):1547-55.
3. MacDonald KP, Hill GR, and Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. *Blood.* 2017;129(1):13-21.
4. Adom D, Rowan C, Adeniyi T, Yang J, and Paczesny S. Biomarkers for Allogeneic HCT Outcomes. *Front Immunol.* 2020;11:673.
5. Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. *Blood.* 2014;123(5):786-93.
6. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, André V, et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. *Transplantation.* 2009;88(11):1261-72.
7. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. *Blood.* 2008;111(6):3276-85.
8. Barak V, Levi-Schaffer F, Nisman B, and Nagler A. Cytokine dysregulation in chronic graft versus host disease. *Leuk Lymphoma.* 1995;17(1-2):169-73.
9. Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, et al. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. *Blood.* 2012;120(20):4246-55.
10. Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, et al. Biomarker Panel for Chronic Graft-Versus-Host Disease. *J Clin Oncol.* 2016;34(22):2583-90.
11. Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M, et al. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. *Biol Blood Marrow Transplant.* 2011;17(12):1804-13.
12. Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. *Blood.* 2016;127(24):3082-91.
13. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S, Noto S, et al. Th2 cytokines (IL-4, IL-10 and IL-13) and IL-12 mRNA expression by concanavalin A-stimulated peripheral blood mononuclear cells during chronic graft-versus-host disease. *Eur J Haematol.* 1996;57(1):111-3.
14. Westekemper H, Meller S, Citak S, Schulte C, Steuhl KP, Homey B, et al. Differential chemokine expression in chronic GVHD of the conjunctiva. *Bone Marrow Transplant.* 2010;45(8):1340-6.
15. Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. *Blood.* 2012;120(12):2529-36.
16. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. *Blood.* 2005;106(8):2903-11.

17. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. *J Clin Invest*. 2010;120(5):1479-93.
18. Brügger MC, Klein I, Greinix H, Bauer W, Kuzmina Z, Rabitsch W, et al. Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. *Blood*. 2014;123(2):290-9.
19. Garchow B, and Kiriakidou M. MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus. *Clin Immunol*. 2016;162:100-6.
20. Shemer R, Magenheimer J, and Dor Y. Digital Droplet PCR for Monitoring Tissue-Specific Cell Death Using DNA Methylation Patterns of Circulating Cell-Free DNA. *Curr Protoc Mol Biol*. 2019;127(1):e90.
21. Moss J, Magenheimer J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nat Commun*. 2018;9(1):5068.
22. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheimer J, Vaknin-Dembinsky A, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. *Proc Natl Acad Sci U S A*. 2016;113(13):E1826-34.
23. Lehmann-Werman R, Magenheimer J, Moss J, Neiman D, Abraham O, Piyanzin S, et al. Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA. *JCI Insight*. 2018;3(12).
24. Magenheimer J, Rokach A, Peretz A, Loyfer N, Cann G, Amini H, et al. Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies. *Eur Respir J*. 2022;60(5).
25. Loyfer N, Magenheimer J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA methylation atlas of normal human cell types. *Nature*. 2023;613(7943):355-64.
26. Lubotzky A, Zemmour H, Neiman D, Gotkine M, Loyfer N, Piyanzin S, et al. Liquid biopsy reveals collateral tissue damage in cancer. *JCI Insight*. 2022;7(2).
27. Fox-Fisher I, Piyanzin S, Ochana BL, Klochendler A, Magenheimer J, Peretz A, et al. Remote immune processes revealed by immune-derived circulating cell-free DNA. *Elife*. 2021;10.
28. Scott M. Lundberg S-IL. *Advances in Neural Information Processing Systems*. 2017:4765-74.
29. Rozmus J, Ivison S, Kariminia A, Leung VM, Sung S, Subrt P, et al. Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. *Bone Marrow Transplant*. 2018;53(10):1263-9.
30. Cheng AP, Cheng MP, Loy CJ, Lenz JS, Chen K, Smalling S, et al. Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. *Proc Natl Acad Sci U S A*. 2022;119(4).
31. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2017;23(2):211-34.
32. Fox-Fisher I, Shemer R, and Dor Y. Epigenetic liquid biopsies: a novel putative biomarker in immunology and inflammation. *Trends Immunol*. 2023;44(5):356-64.

33. Loyfer N, Magenheimer J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A human DNA methylation atlas reveals principles of cell type-specific methylation and identifies thousands of cell type-specific regulatory elements. *bioRxiv*. 2022:2022.01.24.477547.
34. Rozmus J. Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease. *Front Immunol*. 2020;11:574569.
35. Neiman D, Gillis D, Piyanzin S, Cohen D, Fridlich O, Moss J, et al. Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic β cells. *JCI Insight*. 2020;5(14).
36. Refaeilzadeh P, Tang, L., Liu, H. *Encyclopedia of Database Systems*. Springer, Boston, MA; 2009.




Figure 1: characterization of methylation biomarkers. Tissue-specificity of methylation markers for Liver (A), intestinal epithelium (B), lung epithelium (C) and skin (D).





Figure 2: Experimental design.

One hundred and one plasma samples were collected from 101 individuals arriving for planned clinical follow-up, at the BMT day care unit. Upon each visit blood was drawn for regular blood tests and the patient underwent a full assessment by the treating physician which included cGVHD grading according to the 2014 National Institute of Health (NIH) criteria. Ninety-three samples were employed for modeling, excluding those with missing data.

*Abbreviations: cf=cell free; cGVHD=chronic Graft Versus Host Disease; AST- Aspartate transaminase; ALP- Alkaline phosphatase; GGTP- gamma glutamyl transpeptidase.

Figure 3: cfDNA levels correlate with clinical presence of chronic GVHD.

(A) Level of total cfDNA in healthy volunteers, and allogeneic HCT patients with and without clinical signs of cGVHD. **(B-E)** Tissue-specific cfDNA(genome equivalents per ml plasma) in healthy volunteers, allogeneic HCT patients with and without clinical signs of cGVHD, using average signals from methylation markers of skin **(B)**, gastrointestinal tract **(C)**, liver **(D)** and lung **(E)**. Each dot represents one plasma sample. Statistical analysis was performed using non-parametric two-tailed Mann-Whitney test. *Abbreviations: cfDNAng/ml= Total cell free DNA levels in ng/ml. cGVHD=chronic Graft Versus Host Disease; GI= gastrointestinal.






Figure 4: Immune-derived cfDNA levels correlate with clinical presence of chronic GVHD.

Level of immune specific cfDNA in healthy volunteers and allogeneic HCT patients with and without clinical signs of cGVHD, using average signals from methylation markers of neutrophils (A), monocytes (B), eosinophils (C), B cells (D), T cells (E), CD8+ cells (F) and Tregs (G). Each dot represents one plasma sample. Statistical analysis was performed using non-parametric two-tailed Mann-Whitney test. *Abbreviations: cGVHD=chronic Graft Versus Host Disease.





Figure 5: Matrix of correlations between cfDNA and clinical parameters among transplanted patients. Spearman rank correlation coefficient and significance of correlations (*<0.05 **<0.01 ***<0.001).


*Abbreviations: cf=cell free DNA; cfDNAng/ml= Total cell free DNA levels in ng/ml. cGVHD=chronic Graft Versus Host Disease.

Figure 6: Shapley analysis of cfDNA and clinical features. Evaluation of the contribution of each feature to the model's prediction of cGVHD. The parameter space of the model was constrained to be non-negative for all coefficients, thus showing only features with a non negligible coefficient. **(A)** SHAP value distributions **(B)** The average absolute SHAP value for each individual feature (ALT, cfDNA ng/ml, cfMonocytes, cfSkin, GGTP, cfNeutrophils, cfEosinophils).
*Abbreviations: cf=cell free DNA;
cfDNAng/ml=Total cell free DNA levels in ng/ml;
ALT- Alanine transaminase; GGTP- gamma glutamyl transpeptidase.

A



B







Figure 7: Variation of Metrics based on Number of Features. Visual representation of metrics (specificity, sensitivity, AUC, NPV, PPV) based on the addition of features according to their importance as determined by SHAP analysis (purple line=PPV, blue line=specificity, green line=ROC, orange line=sensitivity, red line=NPV).

*Abbreviations: NPV-Negative Predictive Value, PPV-Positive Predictive Value.

Figure 8: Repeated 5-fold cross-validation results on the best feature set.

(A) Bar plot of metrics for solely clinical laboratory features (red; ALT), solely cfDNA features (green; cfDNAng/ml, cfMonocytes) and combined (blue; ALT, cfDNA ng/ml, cfMonocytes) **(B)** ROC curves for solely clinical laboratory features (red; ALT, AUC = 0.65), solely cfDNA features (green; cfDNAng/ml, cfMonocytes; AUC = 0.74) and combined (blue; ALT, cfDNAng/ml, cfMonocytes; AUC = 0.81).
*Abbreviations: cf=cell free DNA; cfDNAng/ml=cell free total DNA levels in ng/ml.

A



B

